Nucleotide Sequences
QTLs in Region (mRatBN7.2)
RGD ID | Symbol | Name | LOD | P Value | Trait | Sub Trait | Chr | Start | Stop | Species | 8552962 | Pigfal16 | Plasma insulin-like growth factor 1 level QTL 16 | 9.4 | blood insulin-like growth factor amount (VT:0010479) | plasma insulin-like growth factor 1 level (CMO:0001299) | 6 | 1 | 41223769 | Rat | 1549905 | Stresp10 | Stress response QTL 10 | 6.83 | 0.0066 | stress-related behavior trait (VT:0010451) | number of approaches toward negative stimulus before onset of defensive burying response (CMO:0001960) | 6 | 1 | 27574569 | Rat | 10401812 | Kidm54 | Kidney mass QTL 54 | kidney mass (VT:0002707) | both kidneys wet weight (CMO:0000085) | 6 | 14368788 | 59368788 | Rat | 1331743 | Uae28 | Urinary albumin excretion QTL 28 | 4.5 | urine albumin amount (VT:0002871) | urine albumin level (CMO:0000130) | 6 | 1 | 34235784 | Rat | 2292589 | Emca10 | Estrogen-induced mammary cancer QTL 10 | 0.048 | mammary gland integrity trait (VT:0010552) | post-insult time to mammary tumor formation (CMO:0000345) | 6 | 16536140 | 61536140 | Rat | 10401800 | Kidm49 | Kidney mass QTL 49 | kidney mass (VT:0002707) | both kidneys wet weight (CMO:0000085) | 6 | 14368788 | 59368788 | Rat | 1300164 | Rf15 | Renal function QTL 15 | 3.12 | renal blood flow trait (VT:2000006) | absolute change in renal blood flow rate (CMO:0001168) | 6 | 5074497 | 54641141 | Rat | 9589129 | Insul24 | Insulin level QTL 24 | 19.06 | 0.001 | blood insulin amount (VT:0001560) | plasma insulin level (CMO:0000342) | 6 | 1 | 41223769 | Rat | 1578758 | Tcas9 | Tongue tumor susceptibility QTL 9 | 3.29 | tongue integrity trait (VT:0010553) | number of squamous cell tumors of the tongue with diameter greater than 3 mm (CMO:0001950) | 6 | 1 | 37618905 | Rat | 4145119 | Mcs25 | Mammary carcinoma susceptibility QTL 25 | 0.0001 | mammary gland integrity trait (VT:0010552) | ratio of deaths to total study population during a period of time (CMO:0001023) | 6 | 10894415 | 110548006 | Rat | 7411603 | Foco13 | Food consumption QTL 13 | 5.5 | 0.001 | eating behavior trait (VT:0001431) | feed conversion ratio (CMO:0001312) | 6 | 1 | 41223769 | Rat | 1598843 | Cm63 | Cardiac mass QTL 63 | 2.6 | heart mass (VT:0007028) | heart weight to body weight ratio (CMO:0000074) | 6 | 1 | 39036266 | Rat | 738024 | Sach5 | Saccharine consumption QTL 5 | 3.9 | 0.00039 | consumption behavior trait (VT:0002069) | saccharin intake volume to total fluid intake volume ratio (CMO:0001601) | 6 | 1 | 43394190 | Rat | 7411542 | Bw127 | Body weight QTL 127 | 5.5 | 0.001 | body mass (VT:0001259) | body weight gain (CMO:0000420) | 6 | 1 | 41223769 | Rat | 9589048 | Scfw3 | Subcutaneous fat weight QTL 3 | 4.57 | 0.001 | subcutaneous adipose mass (VT:1000472) | abdominal subcutaneous fat pad weight (CMO:0002069) | 6 | 1 | 41223769 | Rat | 738023 | Alc17 | Alcohol consumption QTL 17 | 3.1 | 0.003 | consumption behavior trait (VT:0002069) | ethanol drink intake rate to body weight ratio (CMO:0001616) | 6 | 1 | 27574569 | Rat | 1354616 | Despr12 | Despair related QTL 12 | 0.0012 | locomotor behavior trait (VT:0001392) | amount of experiment time spent in a discrete space in an experimental apparatus (CMO:0000958) | 6 | 1 | 27574569 | Rat | 2293839 | Kiddil2 | Kidney dilation QTL 2 | 4.8 | kidney pelvis morphology trait (VT:0004194) | hydronephrosis severity score (CMO:0001208) | 6 | 20866422 | 81133036 | Rat | 1576309 | Emca7 | Estrogen-induced mammary cancer QTL 7 | 4 | mammary gland integrity trait (VT:0010552) | mammary tumor number (CMO:0000343) | 6 | 15107216 | 107351382 | Rat | 2293709 | Bss23 | Bone structure and strength QTL 23 | 5.18 | 0.0001 | femur morphology trait (VT:0000559) | femur cross-sectional area (CMO:0001661) | 6 | 1 | 42487980 | Rat | 2293650 | Bss31 | Bone structure and strength QTL 31 | 5.05 | 0.0001 | femur strength trait (VT:0010010) | femur midshaft polar moment of inertia (CMO:0001669) | 6 | 1 | 42487980 | Rat | 7411584 | Foco4 | Food consumption QTL 4 | 4.3 | 0.001 | eating behavior trait (VT:0001431) | feed conversion ratio (CMO:0001312) | 6 | 1 | 42838846 | Rat | 1578665 | Bss16 | Bone structure and strength QTL 16 | 4.4 | femur morphology trait (VT:0000559) | bone trabecular cross-sectional area (CMO:0002311) | 6 | 11735669 | 72593685 | Rat | 2293841 | Kiddil4 | Kidney dilation QTL 4 | 4.4 | kidney pelvis morphology trait (VT:0004194) | hydronephrosis severity score (CMO:0001208) | 6 | 20866422 | 81133036 | Rat | 2300176 | Bmd51 | Bone mineral density QTL 51 | 11.7 | 0.0001 | femur mineral mass (VT:0010011) | bone mineral density (CMO:0001226) | 6 | 1 | 27574569 | Rat | 1300128 | Rf16 | Renal function QTL 16 | 3.89 | renal blood flow trait (VT:2000006) | absolute change in renal blood flow rate (CMO:0001168) | 6 | 5074497 | 34434305 | Rat | 1641898 | Colcr4 | Colorectal carcinoma resistance QTL4 | 3.71 | 0.0007 | intestine integrity trait (VT:0010554) | well differentiated malignant colorectal tumor surface area measurement (CMO:0002077) | 6 | 20338777 | 62613667 | Rat | 1578668 | Bmd14 | Bone mineral density QTL 14 | 3.8 | femur mineral mass (VT:0010011) | total volumetric bone mineral density (CMO:0001728) | 6 | 11735669 | 72593685 | Rat | 2301972 | Bp325 | Blood pressure QTL 325 | 4.8 | arterial blood pressure trait (VT:2000000) | systolic blood pressure (CMO:0000004) | 6 | 1 | 72227641 | Rat | 2293656 | Bss28 | Bone structure and strength QTL 28 | 6.79 | 0.0001 | femur morphology trait (VT:0000559) | femur midshaft cortical cross-sectional area (CMO:0001663) | 6 | 1 | 42487980 | Rat | 1359023 | Bp272 | Blood pressure QTL 272 | 2.5 | arterial blood pressure trait (VT:2000000) | mean arterial blood pressure (CMO:0000009) | 6 | 16536140 | 27261739 | Rat | 1354664 | Slep2 | Serum leptin concentration QTL 2 | 4.49 | blood leptin amount (VT:0005667) | serum leptin level (CMO:0000780) | 6 | 16536140 | 71636405 | Rat | 2300190 | Bmd52 | Bone mineral density QTL 52 | 11.2 | 0.0001 | femur mineral mass (VT:0010011) | volumetric bone mineral density (CMO:0001553) | 6 | 1 | 27574569 | Rat | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Additional Information